JNJ-90014496: A phase 1/2 trial of JNJ-90014496 in people with relapsed or refractory B-cell non-Hodgkin lymphoma

This trial is testing the medication JNJ-90014496 in adults with B-cell non-Hodgkin lymphoma (NHL) who have disease which has come back after (relapsed) or not responded to (refractory) treatment.

You can share the following isrctn.com Identifier with your medical team so they can find out more about the trial: NCT05421663

Trial aim and background  

The aim of this trial is to find out the safety and efficacy of prizloncabtaggene autoleucel (prizlo-cel) (JNJ-90014496) for the treatment of B-cell NHL. It aims to see what side effects there are, how long the medication stays in the body, and how the body responds to it.

Prizloncabtaggene autoleucel (prizlo-cel) is a bispecific CAR-T therapy which uses a patient’s own T-cells to attack the cancer cells

This is a phase 1b/2 trial. 

Who can enter 

People over 18 with B-cell NHL who have relapsed or refractory disease after two previous treatments may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • University College London Hospitals NHS Foundation Trust, London
  • The Christie NHS Foundation Trust, Manchester

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05421663

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.